Gail Hayward

Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial

Christopher Butler, Richard Hobbs, Oghenekome Gbinigie et al. · The Lancet · 2022 · 391 citations · Full text

Long Covid, Treatment And Prevention, Covid-19 Pandemic +9

Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

Christopher Butler, Jienchi Dorward, Ly‐Mee Yu et al. · The Lancet · 2021 · 306 citations · Full text

Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

Ly‐Mee Yu, Mona Bafadhel, Jienchi Dorward et al. · The Lancet · 2021 · 302 citations · Full text

Epidemiology, Respiratory Diseases, Medicine +6

The zta transactivator involved in induction of lytic cycle gene expression in Epstein-Barr virus-infected lymphocytes binds to both AP-1 and ZRE sites in target promoter and enhancer regions

Paul M. Lieberman, J. Marie Hardwick, Jeffery T. Sample et al. · Journal of Virology · 1990 · 202 citations · Full text

Viral Replication, Zre Sites, Immunology +18

Trends over time in Escherichia coli bloodstream infections, urinary tract infections, and antibiotic susceptibilities in Oxfordshire, UK, 1998–2016: a study of electronic health records

Karina-Doris Vihta, Nicole Stoesser, Martin Llewelyn et al. · The Lancet Infectious Diseases · 2018 · 171 citations · Full text

Urinary Tract Infections, Epidemiology, Epidemiological Trend +12